# WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



#### INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7: WO 00/68265 (11) International Publication Number: A1 C07K 14/47, C12N 15/12, 15/63 (43) International Publication Date: 16 November 2000 (16.11.00) (74) Agents: CADENA, Deborah, L. et al.; Campbell & Flores LLP, PCT/US00/12842 (21) International Application Number: 7th floor, 4370 La Jolla Village Drive, San Diego, CA 92122 (22) International Filing Date: 10 May 2000 (10.05.00) (30) Priority Data:

US

(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application

10 May 1999 (10.05.99)

US

09/309,487

Filed on

09/309,487 (CIP) 10 May 1999 (10.05.99)

(71) Applicant (for all designated States except US): THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 12th floor, 1111 Franklin Street, Oakland, CA 94607-5200 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): SELSTED, Michael, E. [US/US]; 16 Young Court, Irvine, CA 92612 (US). TANG, Yi-Quan [CN/US]; 22 Schubert Court, Irvine, CA 92612 (US). YUAN, Jun [CN/US]; 34 Club Vista, Dove Canyon, CA 92679 (US). OUELLETTE, Andre, J. [US/US]; 32 Harvey Court, Irvine, CA 92612 (US).

(81) Designated States: AE, AG, AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), DM, DZ, EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KR (Utility model), KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD; MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

(54) Title: ANTIMICROBIAL THETA DEFENSINS AND METHODS OF USING SAME

#### (57) Abstract

peptide, present invention relates isolated cyclic theta defensin. having antimicro-The to an activity, and to theta defensin analogs. theta defensin can have the amino acid sequence Xaal-Xaa2-Xaa3-Xaa4-Xaa5-Xaa1-Xaa6-Xaa4-Xaa1-Xaa1-Xaa1-Xaa6-Xaa4-Xaa5-Xaa1-Xaa3-Xaa7-Xaa8, to Xaa8 are defined; wherein Xaa1 can be linked through a peptide bond to Xaa8; and wherein crosslinks can be formed between Xaa3 and Xaa3, between Xaa5 and Xaa5, and between Xaa7 and Xaa7. For example, the invention provides a theta defensin having the amino acid sequence Gly-Phe-Cys-Arg-Cys-Leu- Cys-Arg-Arg-Gly-Val-Cys-Arg-Cys-Ile-Cys-Thr-Arg (SEQ ID NO:1), wherein the Gly at position 1 (Gly-1) is linked through a peptide bond to Arg-18, and wherein disulfide bonds are present between Cys-3 and Cys-16, between Cys-5 and Cys-14, and between Cys-7 and Cys-12. The invention also provides nucleic acids encoding theta defensins and antibodies that specifically bind a theta defensin. In addition, the invention relates to methods of using theta defensin to reduce or inhibit microbial growth or survival.

EXHIBIT A

# **PCT**

### **NOTIFICATION OF ELECTION**

(PCT Rule 61.2)

SELSTED, Michael, E. et al

From the	INT	ERNA'	TIONAL	BUR	EAU
----------	-----	-------	--------	-----	-----

To:

Commissioner
US Department of Commerce
United States Patent and Trademark
Office, PCT
2011 South Clark Place Room
CP2/5C24
Arlington, VA 22202
ETATS-UNIS D'AMERIQUE

Date of mailing (day/month/year)

10 January 2001 (10.01.01)

ETATS-UNIS D'.

in its capacity as elected Office

International application No.
PCT/US00/12842

International filing date (day/month/year)
10 May 2000 (10.05.00)

Applicant

Applicant's or agent's file reference
FP-UC 4131

Priority date (day/month/year)
10 May 1999 (10.05.99)

1.	The designated Office is hereby notified of its election made:	
	X in the demand filed with the International Preliminary Examining Authority on:	
	06 December 2000 (06.12.00)	
	in a notice effecting later election filed with the International Bureau on:	
2.	The election X was	
	was not	
	made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).	

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Authorized officer

Jean-Marc Vivet

Telephone No.: (41-22) 338.83.38

Facsimile No.: (41-22) 740.14.35

J. Aug



To:

#### From the INTERNATIONAL BUREAU

### PCT

### NOTIFICATION CONCERNING SUBMISSION OR TRANSMITTAL OF PRIORITY DOCUMENT

(PCT Administrative Instructions, Section 411)

CADENA, Deborah, L. Campbell & Flores LLP 7th floor

4370 La Jolla Village Drive San Diego, CA 92122 ETATS-UNIS D'AMERIQUE

31 July 2001 (31.07.01)	Description of the following of the process of the control of the		
Applicant's or agent's file reference FP-UC 4131	IMPORTANT NOTIFICATION		
International application No. PCT/US00/12842	International filing date (day/month/year) 10 May 2000 (10.05.00)		
International publication date (day/month/year) 16 November 2000 (16.11.00)	Priority date (day/month/year) 10 May 1999 (10.05.99)		
Applicant THE REGENTS OF THE UNIVERSITY OF CALIFO	DRNIA et al		

- 1. The applicant is hereby notified of the date of receipt (except where the letters "NR" appear in the right-hand column) by the International Bureau of the priority document(s) relating to the earlier application(s) indicated below. Unless otherwise indicated by an asterisk appearing next to a date of receipt, or by the letters "NR", in the right-hand column, the priority document concerned was submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b).
- 2. This updates and replaces any previously issued notification concerning submission or transmittal of priority documents.
- 3. An asterisk(\*) appearing next to a date of receipt, in the right-hand column, denotes a priority document submitted or transmitted to the International Bureau but not in compliance with Rule 17.1(a) or (b). In such a case, the attention of the applicant is directed to Rule 17.1(c) which provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.
- 4. The letters "NR" appearing in the right-hand column denote a priority document which was not received by the International Bureau or which the applicant did not request the receiving Office to prepare and transmit to the International Bureau, as provided by Rule 17.1(a) or (b), respectively. In such a case, the attention of the applicant is directed to Rule 17.1(c) which provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.

Priority date Priority application No. Country or regional Office or PCT receiving Office of priority document

10 May 1999 (10.05.99) 09/309,487 US 03 July 2001 (03.07.01)

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Authorized officer

S. Mandallaz

Facsimile No. (41-22) 740.14.35

Telephone No. (41-22) 338.83.38

#### WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



### INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7: WO 00/68265 (11) International Publication Number: **A1** C07K 14/47, C12N 15/12, 15/63 (43) International Publication Date: 16 November 2000 (16.11.00)

PCT/US00/12842 (21) International Application Number:

US

(22) International Filing Date: 10 May 2000 (10.05.00)

10 May 1999 (10.05.99)

(63) Related by Continuation (CON) or Continuation-in-Part

(CIP) to Earlier Application US 09/309,487 (CIP) 10 May 1999 (10.05.99) Filed on

(71) Applicant (for all designated States except US): REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 12th floor, 1111 Franklin Street, Oakland, CA 94607-5200 (US).

(72) Inventors; and

(30) Priority Data:

09/309,487

(75) Inventors/Applicants (for US only): SELSTED, Michael, E. [US/US]; 16 Young Court, Irvine, CA 92612 (US). TANG, Yi-Quan [CN/US]; 22 Schubert Court, Irvine, CA 92612 (US). YUAN, Jun [CN/US]; 34 Club Vista, Dove Canyon, CA 92679 (US). OUELLETTE, Andre, J. [US/US]; 32 Harvey Court, Irvine, CA 92612 (US).

(74) Agents: CADENA, Deborah, L. et al.; Campbell & Flores LLP, 7th floor, 4370 La Jolla Village Drive, San Diego, CA 92122 (US).

(81) Designated States: AE, AG, AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), DM, DZ, EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KR (Utility model), KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published** 

With international search report.

(54) Title: ANTIMICROBIAL THETA DEFENSINS AND METHODS OF USING SAME

#### (57) Abstract

invention relates isolated cyclic peptide. theta defensin, having antimicro-The present an to to theta defensin analogs. theta defensin can have the amino acid sequence activity, and  $X_{aa1}-X_{aa2}-X_{aa3}-X_{aa4}-X_{aa5}-X_{aa1}-X_{aa6}-X_{aa4}-X_{aa4}-X_{aa4}-X_{aa1}-X_{aa6}-X_{aa4}-X_{aa5}-X_{aa1}-X_{aa5}-X_{aa7}-X_{aa8}$ wherein Xaal to Xaa8 are defined; wherein Xaa1 can be linked through a peptide bond to Xaa8; and wherein crosslinks can be formed between Xaa3 and Xaa3, between Xaa5 and Xaa5, and between Xaa7 and Xaa7. For example, the invention provides a theta defensin having the amino acid sequence Gly-Phe-Cys-Arg-Cys-Leu- Cys-Arg-Arg-Gly-Val-Cys-Arg-Cys-Ile-Cys-Thr-Arg (SEQ ID NO:1), wherein the Gly at position 1 (Gly-1) is linked through a peptide bond to Arg-18, and wherein disulfide bonds are present between Cys-3 and Cys-16, between Cys-5 and Cys-14, and between Cys-7 and Cys-12. The invention also provides nucleic acids encoding theta defensins and antibodies that specifically bind a theta defensin. In addition, the invention relates to methods of using theta defensin to reduce or inhibit microbial growth or survival.

# FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
ΑT	Austria	FR	France	LU	Luxembourg	SN	Senegal
ΑU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
ΑZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
ВJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of Americ
CA	Canada	IТ	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JР	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	zw	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore	•	

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07K14/47 C12N15/12 C12N15/63

According to International Patent Classification (IPC) or to both national classification and IPC

### B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched


Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, STRAND, CHEM ABS Data, BIOSIS

C. DOCUM	C. DOCUMENTS CONSIDERED TO BE RELEVANT					
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.				
A	TANG, YI-QUAN ET AL: "A cyclic antimicrobial peptide produced in primate leukocytes by the ligation of two truncated.alphadefensins" SCIENCE (WASHINGTON, D. C.) (1999), 286(5439), 498-502, 1999, XP000919300 Figs. 2-3	2-32, 34-38, 40-49, 51-83				
P, X	TAM, JAMES P. ET AL: "Marked increase in membranolytic selectivity of novel cyclic tachyplesins constrained with an antiparallel twobeta. strand cystine knot framework" BIOCHEM. BIOPHYS. RES. COMMUN. (2000), 267(3), 783-790, 2000, XP000917243 Figures	2-32, 34-38, 40-49, 51-83				
	-/					

Further documents are listed in the continuation of box C.	Patent family members are listed in annex.
Special categories of cited documents:  A' document defining the general state of the art which is not considered to be of particular relevance  E' earlier document but published on or after the international filing date  L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  O' document referring to an oral disclosure, use, exhibition or other means  P' document published prior to the international filing date but later than the priority date claimed	<ul> <li>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</li> <li>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</li> <li>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</li> <li>"8" document membe "es same patent family</li> </ul>
Date of the actual completion of the international search 7 August 2000	Date of mailing of the international search report  2 4, 08, 00
Name and mailing address of the ISA  European Patent Office, P.B. 5818 Patentiaan 2  NL - 2280 HV Rijswijk  Tel. (+31-70) 340-2040, Tx. 31 651 epu nl,  Fax: (+31-70) 340-3016	Authorized officer  Kronester-Frei, A

2



Intern 1al Application No PCT/US 00/12842

Category *	tion) DOCUMENTS CONSIDERED TO BE RELEVANT  Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 99 11663 A (BOUGUELERET LYDIE ;CHUMAKOV ILYA (FR); GENSET (FR)) 11 March 1999 (1999-03-11)	2-32, 34-38, 40-49,
	CLAIMS, EXAMPLES	51-83
A	WO 99 13080 A (ZYMOGENETICS INC) 18 March 1999 (1999-03-18)	2-32, 34-38, 40-49,
	claims, examples	51-83
A	WO 96 16075 A (UNIV CALIFORNIA ; SHRINER S HOSPITAL FOR CRIPPLE (US)) 30 May 1996 (1996-05-30)	2-32, 34-38, 40-49, 51-83
	claims	31 03
•		
,		

2

Inc. national application No. PCT/US 00/12842

Box I Observations where certain claims were found uns archable (Continuation	f item 1 of first sheet)
This International Search Report has not been established in respect of certain claims under Article	7(2)(a) for the following reasons:
1. X Claims Nos.: 83 because they relate to subject matter not required to be searched by this Authority, namely	
see FURTHER INFORMATION sheet PCT/ISA/210	
Claims Nos.: 1,33,39,50     because they relate to parts of the International Application that do not comply with the presan extent that no meaningful International Search can be carried out, specifically:	scribed requirements to such
see FURTHER INFORMATION sheet PCT/ISA/210	
Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and	third sentences of Rule 6.4(a).
Box II Observations where unity of invention is lacking (Continuation of item 2 of	lirst sheet)
This International Searching Authority found multiple inventions in this international application, as fo	llows:
·	
As all required additional search fees were timely paid by the applicant, this International Seserchable claims.	earch Report covers all
2. As all searchable claims could be searched without effort justifying an additional fee, this Ai of any additional fee.	uthority did not invite payment
As only some of the required additional search fees were timely paid by the applicant, this I covers only those claims for which fees were paid, specifically claims Nos.:	nternational Search Report
·	
4. No required additional search fees were timely paid by the applicant. Consequently, this Intrestricted to the invention first mentioned in the claims; it is covered by claims Nos.:	ernational Search Report is
Remark: Protest The additional search fees were accom	
No protest acce anied the payment of	f additional search fees.

### FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claim 83 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.1

Claims Nos.: 83

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

Continuation of Box I.2

Claims Nos.: 1,33,39,50

Present claims 1, 33, 39, 50 (functional fragment thereof) and dependent subject-matter relate to an extremely large number of possible peptides/pharmaceutical compositions/nucleic acids/vectors. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the peptides/pharmaceutical compositions/nucleic acids/vectors claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the peptides/pharmaceutical compositions/nucleic acids/vectors being prepared in the examples and closely related homologous compounds etc./those compounds etc. mentioned in the description at pages 12, lines 14 to pages 17, lines 16.

Inter inal Application No PCT/US 00/12842

	atent document d in search report		Publication date	F	Patent family member(s)	Publication date
WO	9911663	A	11-03-1999	FR AU EP	2767832 A 9079898 A 1009767 A	05-03-1999 22-03-1999 21-06-2000
WO	9913080	Α	18-03-1999	AU EP	9391598 A 1012285 A	29 <b>-</b> 03-1999 28 <b>-</b> 06-2000
WO	9616075	A	30-05-1996	US AU AU EP JP US US US	5844072 A 697378 B 3958795 A 0792279 A 10509047 T 6057425 A 5840498 A 5731149 A 9508887 A	01-12-1998 01-10-1998 17-06-1996 03-09-1997 08-09-1998 02-05-2000 24-11-1998 24-03-1998 09-05-1996

# PCT

# INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

pplicant's or agent's file re	FOR FURTH ACTION		of Transmittal of International Search 220) as well as, where applicable, iter	
ternational application No	o. International filing de	ate (day/month/year)	(Earliest) Priority Date (day/month	ı/year)
CT/US 00/12842	10/0:	5/2000	10/05/1999	
pplicant				
			·	
HE REGENRIS OF	THE UNIVERSITY OF CALI	-ORN1A		
according to Article 18. A	Report has been prepared by this Intecopy is being transmitted to the International Report consists of a total of5	ational Bureau.	nority and is transmitted to the applic	ant
1777	accompanied by a copy of each prior a	sheets. rt document cited in this	report.	
. Basis of the report				
	e <b>language,</b> the international search w h it was filed, unless otherwise indicate		sis of the international application in t	ne
		•		
	ational search was carried out on the b (Rule 23.1(b)).	asis of a translation of t	he international application furnished	to this
was carried out o	y <b>nucleotide and/or amino acid sequ</b> n the basis of the sequence listing :	•	ternational application, the internation	nal search
	d in the international application in writt			
	ther with the international application in	•	n.	
	subsequently to this Authority in writte		*	
<u> </u>	subsequently to this Authority in comp			
	ment that the subsequently furnished w nal application as filed has been furnis		loes not go beyond the disclosure in t	he
the states	ment that the information recorded in o	omputer readable form i	s identical to the written sequence list	ing has beer
turnisneo				
. X Certain o	claims were found unsearchable (Se	e Box I).	*	
=	invention is lacking (see Box II).	•		
		*		
With regard to the <b>titl</b>				
· ram	s approved as submitted by the applica	int.		
	as been established by this Authority to		·	
L. Indiana	as seen cotasiisned by time nationly t	5 10 LL LD 10110110.	•	
			·	
·			. •	
Mith roaded to the ab	atunat			
. With regard to the <b>ab</b>			•	•
the text h	approved as submitted by the applica as been established, according to Rule e month from the date of mailing of this	≥ 38.2(b), by this Authori		
The figure of the <b>dra</b> v	wings to be published with the abstrac	t is Figure No.		
as sugge	sted by the applicant.		X None of the f	igures.
=	the applicant failed to suggest a figure.			
				•

# FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claim 83 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.1

Claims Nos.: 83

Rule 39.1(iv) PCT — Method for treatment of the human or animal body by therapy

Continuation of Box I.2

Claims Nos.: 1,33,39,50

Present claims 1, 33, 39, 50 (functional fragment thereof) and dependent subject-matter relate to an extremely large number of possible peptides/pharmaceutical compositions/nucleic acids/vectors. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the peptides/pharmaceutical compositions/nucleic acids/vectors claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the peptides/pharmaceutical compositions/nucleic acids/vectors being prepared in the examples and closely related homologous compounds etc./those compounds etc. mentioned in the description at pages 12, lines 14 to pages 17, lines 16.

International Application No PCT/US 00/12842

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07K14/47 C12N15/12 C12N15/63

According to International Patent Classification (IPC) or to both national classification and IPC

### B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  $IPC \ 7 \ C07K \ C12N$ 

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, STRAND, CHEM ABS Data, BIOSIS

	INTS CONSIDERED TO BE RELEVANT	<u> </u>
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	TANG, YI-QUAN ET AL: "A cyclic antimicrobial peptide produced in primate leukocytes by the ligation of two truncated.alphadefensins" SCIENCE (WASHINGTON, D. C.) (1999), 286(5439), 498-502, 1999, XP000919300 Figs. 2-3	2-32, 34-38, 40-49, 51-83
Ρ,Χ	TAM, JAMES P. ET AL: "Marked increase in membranolytic selectivity of novel cyclic tachyplesins constrained with an antiparallel twobeta. strand cystine knot framework" BIOCHEM. BIOPHYS. RES. COMMUN. (2000), 267(3), 783-790, 2000, XP000917243 Figures	2-32, 34-38, 40-49, 51-83

X Further documents are listed in the continuation of box C.	χ Patent family members are listed in annex.
<ul> <li>Special categories of cited documents:</li> <li>"A" document defining the general state of the art which is not considered to be of particular relevance</li> <li>"E" earlier document but published on or after the international filling date</li> <li>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</li> <li>"O" document referring to an oral disclosure, use, exhibition or other means</li> <li>"P" document published prior to the international filling date but later than the priority date claimed</li> </ul>	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.  "&" document member of the same patent family
Date of the actual completion of the international search  7 August 2000	Date of mailing of the international search report
Name and mailing address of the ISA  European Patent Office, P.B. 5818 Patentlaan 2  NL - 2280 HV Rijswijk  Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  Fax: (+31-70) 340-3016	Authorized officer  Kronester-Frei, A

2

International Application No PCT/US 00/12842

	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	Delayant to allow Ma
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 99 11663 A (BOUGUELERET LYDIE ;CHUMAKOV ILYA (FR); GENSET (FR)) 11 March 1999 (1999-03-11)	2-32, 34-38, 40-49,
	CLAIMS, EXAMPLES	51-83
A	WO 99 13080 A (ZYMOGENETICS INC) 18 March 1999 (1999-03-18)	2-32, 34-38, 40-49, 51-83
	claims, examples	31 63
Α	WO 96 16075 A (UNIV CALIFORNIA ;SHRINER S HOSPITAL FOR CRIPPLE (US)) 30 May 1996 (1996-05-30)	2-32, 34-38, 40-49,
	claims	51-83
	·	·

formation on patent family members

International Application No PCT/US 00/12842

Patent document cited in search report			Publication date	Patent family member(s)		Publication date	
WO 9	9911663	A	11-03-1999	FR AU EP	2767832 A 9079898 A 1009767 A	Ą	05-03-1999 22-03-1999 21-06-2000
WO 9	9913080	A	18-03-1999	AU E P	9391598 A 1012285 A		29-03-1999 28-06-2000
WO 9	9616075	Α	30-05-1996	US AU EP JP US US ZA	5844072 A 697378 B 3958795 A 0792279 A 10509047 T 6057425 A 5840498 A 5731149 A 9508887 A	3 A A T A A	01-12-1998 01-10-1998 17-06-1996 03-09-1997 08-09-1998 02-05-2000 24-11-1998 24-03-1998 09-05-1996